文献速递临床试验与 GCP流行病学与生物统计

宫颈环扎与宫颈托联合或不联合阴道孕酮预防双胎妊娠宫颈短者早产:二乘二析因随机临床试验

Cervical cerclage versus cervical pessary with or without vaginal progesterone for preterm birth prevention in twin pregnancies and a short cervix: A two-by-two factorial randomised clinical trial.
PubMed 文献 · PLoS Med · 2025-02-21

在越南胡志明市2家医院开展的多中心二乘二析因随机试验,纳入219例妊娠16至22周、宫颈长度≤28 mm的无症状双胎妊娠妇女,比较宫颈环扎与Arabin宫颈托及加用400 mg阴道孕酮与否的效果。环扎组与宫颈托组早产<34周发生率相近(19.8% vs 19%,RR 1.04;95%CI 0.60至1.8),但环扎组早产<28周(1% vs 8.6%,RR 0.12;95%CI 0.01至0.52)和围产儿死亡(1% vs 5.8%,RR 0.17;95%CI 0.05至0.62)显著更低。研究因环扎组围产儿死亡和<28周分娩率显著更低而提前终止。

要点

  • 双胎妊娠宫颈长度≤28 mm者,宫颈环扎与宫颈托预防早产<34周效果相当(19.8% vs 19%,RR 1.04;95%CI 0.60至1.8)。
  • 环扎组早产<28周(1% vs 8.6%,RR 0.12;95%CI 0.01至0.52)和围产儿死亡(1% vs 5.8%,RR 0.17;95%CI 0.05至0.62)显著低于宫颈托组。
  • 加用400 mg阴道孕酮与未加用者早产<34周无显著差异(18.4% vs 20.4%,RR 0.90;95%CI 0.52至1.6)。

核心结论

  • 在双胎妊娠且宫颈长度≤28 mm者中,宫颈环扎与宫颈托预防早产<34周效果相当,但环扎与更低的早产<28周率和围产儿死亡率相关。

研究设计与样本

  • 多中心二乘二析因随机临床试验,在越南胡志明市2家医院开展。
  • 纳入219例妊娠16至22周、宫颈长度≤28 mm的无症状双胎妊娠妇女,随机分为环扎加孕酮(n=55)、Arabin宫颈托加孕酮(n=56)、单纯环扎(n=54)或单纯Arabin宫颈托(n=54)。
  • 主要结局为早产<34周;研究在第二次中期分析后因环扎组围产儿死亡和<28周分娩率显著更低而提前终止。

主要发现

  • 主要结局早产<34周在环扎组20例(19.8%)与宫颈托组20例(19%)之间无显著差异(RR 1.04;95%CI 0.60至1.8)。
  • 早产<28周在环扎组为1%、宫颈托组为8.6%(RR 0.12;95%CI 0.01至0.52)。
  • 围产儿死亡在环扎组为1%、宫颈托组为5.8%(RR 0.17;95%CI 0.05至0.62)。
  • 早产<24周、<32周及其他新生儿结局在两组间无显著差异。
  • 阴道分泌物在环扎组显著更少。

关键数值与推荐

  • 分配至孕酮组者早产<34周19例(18.4%),未用孕酮者21例(20.4%),RR 0.90;95%CI 0.52至1.6。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因环扎组围产儿死亡和<28周分娩率显著更低而提前终止,仅随机219例(为计划样本量的64.4%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnant women with twins and a short cervical length (CL) are at greater risk of preterm birth (PTB). The comparative efficacy of cervical cerclage and cervical pessary with or without additional progesterone to prevent PTB is unknown. We aimed to assess, in women with twin pregnancies and a short CL, the effectiveness of cerclage versus pessary and the additional treatment with 400 mg vaginal progesterone versus no progesterone in preventing PTB. METHODS AND FINDINGS: This multicenter, two-by-two factorial randomised trial was conducted in 2 hospitals in Ho Chi Minh City, Vietnam. Asymptomatic women with twin pregnancies and a CL ≤28 mm at 16 to 22 gestational weeks were recruited. Between March 2019 and July 2023, we randomised 219 participants (64.4% of the planned sample size) to cerclage plus progesterone (n = 55), Arabin pessary plus progesterone (n = 56), cerclage alone (n = 54) or Arabin pessary alone (n = 54). Primary outcome was any PTB <34 weeks. Following the second interim analysis, the study was terminated due to significantly lower rates of perinatal deaths and deliveries <28 weeks in the cerclage group. The primary outcome occurred in 20 (19.8%) participants receiving cerclage versus 20 (19%) participants receiving pessary (relative risk [RR] 1.04; 95% confidence interval [CI], 0.60 to 1.8). Delivery <28 weeks occurred in 1% versus 8.6% (RR 0.12; 95% CI, 0.01 to 0.52) and perinatal death occurred in 1% versus 5.8% (RR 0.17; 95% CI, 0.05 to 0.62) in the cerclage group and the pessary group, respectively. However, PTB <24 weeks, <32 weeks, and other neonatal outcomes were not significantly different between the 2 groups. For maternal side effects, vaginal discharge was significantly less frequent in the cerclage group. In participants allocated to progesterone, PTB <34 weeks occurred in 19 (18.4%) versus 21 (20.4%) participants who did not have progesterone (RR 0.90; 95% CI, 0.52 to 1.6). CONCLUSIONS: In this prematurely halted study on pregnant women with twins and a CL ≤28 mm, cerclage and cervical pessary were comparably effective on PTB <34 weeks prevention. However, compared to pessary, cerclage was associated with significantly lower rates of PTB <28 weeks and perinatal mortality. ClinicalTrials.gov Registration: NCT03863613 (https://clinicaltrials.gov/study/NCT03863613).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. He YTN, Pham HNH, Nguyen TC, et al. Cervical cerclage versus cervical pessary with or without vaginal progesterone for preterm birth prevention in twin pregnancies and a short cervix: A two-by-two factorial randomised clinical trial. PLoS Med. 2025. PMID: 39982935. doi:10.1371/journal.pmed.1004526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。